These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33161728)

  • 1. The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia.
    Khan MS; Butler J; Greene SJ
    Circ Heart Fail; 2020 Dec; 13(12):e008030. PubMed ID: 33161728
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium-glucose co-transporter 2 inhibitors and acute heart failure.
    Groenewegen A; Rutten FH
    Eur J Heart Fail; 2020 Apr; 22(4):723-725. PubMed ID: 32072715
    [No Abstract]   [Full Text] [Related]  

  • 3. The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox.
    Carbone S; daSilva-deAbreu A; Lavie CJ
    Eur J Heart Fail; 2021 Oct; 23(10):1673-1676. PubMed ID: 34427026
    [No Abstract]   [Full Text] [Related]  

  • 4. Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.
    Liang B; Gu N
    Int J Med Sci; 2022; 19(7):1118-1121. PubMed ID: 35919809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!
    Katsiki N; Rizzo M; Mikhailidis DP
    J Diabetes Complications; 2023 Jul; 37(7):108510. PubMed ID: 37235924
    [No Abstract]   [Full Text] [Related]  

  • 6. Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure.
    Patoulias D; Papadopoulos C; Doumas M
    J Stroke Cerebrovasc Dis; 2022 Mar; 31(3):106257. PubMed ID: 34953683
    [No Abstract]   [Full Text] [Related]  

  • 7. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
    Katsiki N; Triposkiadis F
    Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
    [No Abstract]   [Full Text] [Related]  

  • 8. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
    Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
    [No Abstract]   [Full Text] [Related]  

  • 9. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
    Bocchi EA; Biolo A; Moura LZ; Figueiredo Neto JA; Montenegro CEL; Albuquerque DC
    Arq Bras Cardiol; 2021 Feb; 116(2):355-358. PubMed ID: 33656089
    [No Abstract]   [Full Text] [Related]  

  • 10. The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction.
    Verma S
    Cardiovasc Res; 2020 Jan; 116(1):e8-e10. PubMed ID: 31850505
    [No Abstract]   [Full Text] [Related]  

  • 11. Dapagliflozin (Farxiga) - a new indication for heart failure.
    Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
    [No Abstract]   [Full Text] [Related]  

  • 12. Sodium-glucose co-transporter-2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness.
    Khunti K; Kosiborod M
    Diabetes Obes Metab; 2018 Apr; 20(4):763-765. PubMed ID: 29077267
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
    Butler J; Anker SD; Filippatos G; Usman MS; Ferreira JP; Zannad F; Packer M
    Eur Heart J; 2021 Dec; 42(48):4887-4890. PubMed ID: 34718518
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to: Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Yalta
    Joshi SS; Singh T; Singh J; Newby DE
    Heart; 2021 Dec; 107(23):1922-1923. PubMed ID: 34656972
    [No Abstract]   [Full Text] [Related]  

  • 15. Sodium-glucose co-transporter 2 inhibitors in heart failure.
    Rosano GMC; Vitale C; Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e9-e10. PubMed ID: 33576409
    [No Abstract]   [Full Text] [Related]  

  • 16. Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Joshi
    Yalta K; Ozkan U; Yalta T
    Heart; 2021 Dec; 107(23):1922. PubMed ID: 34656974
    [No Abstract]   [Full Text] [Related]  

  • 17. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
    Savarese G; Sattar N; Januzzi J; Verma S; Lund LH; Fitchett D; Zeller C; George JT; Brueckmann M; Ofstad AP; Inzucchi SE; Wanner C; Zinman B; Butler J
    Circulation; 2019 Mar; 139(11):1458-1460. PubMed ID: 30855996
    [No Abstract]   [Full Text] [Related]  

  • 18. Empagliflozin Targeting the Real-World Heart Failure Population.
    Rocha BML; Gomes RV; Cunha GJL; Mendes G; Morais R; Campos L; Araújo I; Fonseca C
    J Card Fail; 2019 Mar; 25(3):218-219. PubMed ID: 30743044
    [No Abstract]   [Full Text] [Related]  

  • 19. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin (Farxiga) for Preventing Hospitalization for Heart Failure.
    Tingen J; Gazewood JD
    Am Fam Physician; 2020 Jul; 102(2):115-116. PubMed ID: 32667164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.